Glaxosmithkline | GSK - Sales Revenues

Stock Price
54.49
Daily Change
-4.63 -7.83%
Monthly
-8.05%
Yearly
39.83%
Q2 Forecast
53.52

Glaxosmithkline reported GBP10.09B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bausch Health Companies USD 2.8B 120M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Zoetis USD 2.4B 0 Dec/2025